Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II-III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy

Radu Valeriu Toma; Zgura Anca; Oana Gabriela Trifănescu; Laurenția Nicoleta Galeș; Antonia Ruxandra Folea; Loredana Stanca; Liviu Bîlteanu; Rodica M. Anghel

doi:10.12659/MSM.941754

20 September 2023 : Clinical Research

Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II-III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy

Radu Valeriu Toma^{^A Study design/planning

^B Data collection/entry

^C Data analysis/statistics

^G Funds collection

" data-author="4365589">12ABCG}, Zgura Anca^1E, Oana Gabriela Trifănescu^{^A Study design/planning

" data-author="4365591">12A}, Laurenția Nicoleta Galeș^{^D Data interpretation

^*Corresponding author: [email protected]
^*Corresponding author: [email protected]
" data-author="4365592">12D*}, Antonia Ruxandra Folea^{^C Data analysis/statistics

^D Data interpretation

^E Preparation of manuscript

^F Literature analysis/search

" data-author="4365593">2CDEF}, Loredana Stanca^3B, Liviu Bîlteanu^{³Department of Preclinical Science, Faculty of Veterinary Medicine, University of Agronomic Sciences and Veterinary Medicine, Bucharest, Romania
⁴Laboratory of Molecular Nanotechnologies, National Institute for Research and Development in Microtechnologies, Voluntary, Romania

^A Study design/planning

^B Data collection/entry

^C Data analysis/statistics

^D Data interpretation

^E Preparation of manuscript

^F Literature analysis/search

" data-author="4365595">234ABCDEF}, Rodica M. Anghel^1A

DOI: 10.12659/MSM.941754

Med Sci Monit 2023; 29:e941754

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 3 Independent predictors (univariate models) of the downward evolution of EF after CHT administration: the evolution of echo- and electrocardiographic semiology, the doses of CHT and RT, and with the cardiac preconditioning at the beginning of the treatment. The 95% confidence intervals are plotted in a logarithmic scale (from 1 to 1000) for OR and (from 1 to 10) for RR.

Back to the Article

Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II-III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy

Your Privacy